This page shows the latest chronic lung disease news and features for those working in and with pharma, biotech and healthcare.
All participants in this trial had at least one risk factor for developing severe COVID-19, including chronic lung disease, obesity, cardiovascular disease or were at least 50 years of age. ... high-risk of severe disease or hospitalisation.
All participants in this trial had at least one risk factor for developing severe COVID-19, including chronic lung disease, obesity, cardiovascular disease or were at least 50 years of age. ... In the US, REGEN-COV is authorised for emergency use to
palivizumab) among preterm infants and children with chronic lung disease (CLD) and congenital heart disease (CHD).
This includes influenza patients who have conditions including asthma, chronic lung disease, diabetes, heart disease or morbid obesity or adults aged 65 and over.
On Wednesday, the European Commission granted Moderna’s COVID-19 vaccine, initially called mRNA-1273, a conditional marketing authorisation to prevent the disease in people aged 18 years and older. ... The trial also showed a 90.9% efficacy rate in
The trial also showed a 90.9% efficacy rate in participants who were at risk of developing severe COVID-19 infection, including people with chronic lung disease, heart disease, obesity, liver ... disease, diabetes or HIV infection.
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
People with chronic conditions such as diabetes, lung disease, and heart disease, and those of advanced age, had a poorer prognosis once infected with COVID-19. ... In the U.S., fewer healthcare providers have training, knowledge, and expertise in
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...